“Promising research is not a daily mushroom multivitamin—or proven TBI repair.”
“Psilocybin microdoses are a non-hallucinogenic daily supplement that broadly improves health and has the fastest results for traumatic-brain-injury recovery.”
Psilocybin is metabolized to psilocin, which acts primarily as a serotonin 5-HT2A receptor agonist. Research and federal policy activity exist around psychedelic treatments, and psilocybin-assisted therapy has shown potential for selected conditions such as depression and some substance-use disorders in controlled settings.
The White House order accelerated research and regulatory review; it did not federally approve psilocybin for medical use. Evidence does not establish microdosing as a safe, effective daily wellness additive, and controlled studies have not shown broad cognitive or well-being benefits. There is no evidence that psilocybin heals brain lesions or produces the fastest TBI recovery; the relevant concussion study is a small, ongoing phase 1 trial with no posted results. The video’s claim that receptors are shut down and a person’s identity is never the same is not an accurate account of the drug’s pharmacology or established outcomes.
The omissions are material because the post turns early, supervised research into a recommendation for routine self-treatment across many serious medical conditions, including TBI.
Why Clear says this
Potential benefits from clinical psilocybin research generally involve screened participants, measured doses, psychological support, and specific conditions. That evidence cannot support the post’s sweeping disease list or its claim of proven, rapid TBI recovery. Microdoses can still cause noticeable effects and adverse effects, including anxiety, increased blood pressure, and cognitive impairment.
Evidence
- The April 18, 2026 executive order directs agencies to speed research, data sharing, and review pathways for psychedelic drugs; it does not approve psilocybin as a treatment.
- NCCIH says it is unclear whether psilocybin microdosing is safe or effective and notes possible adverse effects including anxiety, depression, insomnia, gastrointestinal symptoms, poor focus, and impaired social functioning.
- A placebo-controlled psilocybin-microdosing trial found no evidence of enhanced well-being, creativity, or cognitive function, with some changes toward cognitive impairment.
- The registered TBI/concussion study is recruiting, phase 1, enrolls an estimated 40 people, and has no results posted; it tests feasibility and safety rather than demonstrating recovery or lesion healing.
- Psilocybin’s active metabolite is a serotonin-receptor agonist, not a mechanism that shuts serotonin receptors down completely.